The Two-Fold Drawback So Far As Ovarian Cancer Treatment Is Concerned

Late stage ovarian cancer has been hard to get rid of. It has been a nightmare for women who discover that they have cancerous cysts in their ovaries. This is why the news that GlaxoSmithkline was withdrawing its application to expand the approval of Votrient is disappointing.
Votrient is the ‘miracle’ drug that has been used in the treatment of sarcomas and kidney cancer in various countries. It does this by restricting supply to tumors and hence limiting their growth or spread.
This is however not just a disappointment to women with cancerous cysts in their ovaries. As a drug, Votrient has proven to be really profitable for GSK. The drug was solely responsible for bringing in over $520 million in last year sales alone.
The reason for the cancellation of the bid to have it made available for patients with ovarian cancer has been sighted as being the results from a Phase III trial. According to the company’s head of Oncology Research and Development, Rafael Amado, the results showed that the benefits of the drug did not outweigh its negative effects.
Rafael Amado comment on possible cancerous ovarian cyst treatment
Rafael Amado
Maintaining a positive outlook, he added:
“While we are disappointed by the results, we will progress with additional analyses which may add to the body of scientific evidence in this disease setting.”